Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate cancer cel

Trial Details

NCT ID
NCT06526299
Phase
PHASE2
Sponsor
University of Washington
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Biospecimen Collection
  • Bone Scan
  • Computed Tomography
  • Lutetium Lu 177 Vipivotide Tetraxetan
  • Magnetic Resonance Imaging
  • PSMA PET-CT Scan
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Sylmar, California, United States|34.30778,-118.44925
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Patients must have the ability to understand and sign an approved informed consent.
  • Patients must have the ability to understand and comply with all protocol requirements.
  • Patients must be ≥ 18 years of age.
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →